Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Molecules › HS-20094

HS-20094

GIP/GLP-1 · s.c. · Hansoh

Data cut 12 November 2026 · page built 16 November 2026 · 3 trial arms · 1 trials with results · 4 registered trials · see on the pipeline board

Summary

Also known as
Hansoh (Regeneron licence ex-China)
Mechanism
GIP/GLP-1
Route
s.c.
Company
Hansoh
Highest development stage
filed
Status (as of data cut)
Olatorepatide. Phase 3 LIGHTEN positive in China (−18.7 % at 48 weeks, EASD 2026); NDA accepted (June 2026); Regeneron licence ex-China verify
Next milestone
China approval; global phase 3 (Regeneron)

Indications: regulatory and evidence status

IndicationCodeStatusEvidence
Obesity3 positive phase 3Positive phase 3 LIGHTEN (EASD 2026); NDA accepted June 2026LIGHTEN (EASD 2026); Hansoh NDA announcement (Jun 2026)
T2D2 phase 3 ongoingPhase 3 registered on ClinicalTrials.gov
CV outcomes0 no data
CKD0 no data
HFpEF0 no data
MASH0 no data
Sleep apnoea0 no data
Knee OA0 no data
Alzheimer's0 no data

4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.

Trial arms: weight, HbA1c and tolerability

TrialArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
LIGHTEN (HS-20094-301)5 mgobesity china48604−12.5 % vs −2.7 %
Δ −9.8 pp
−11.8 % vs −2.5 %
Δ −9.3 pp
———————congress
LIGHTEN (HS-20094-301)10 mgobesity china48604−17.5 % vs −2.7 %
Δ −14.8 pp
−17.0 % vs −2.5 %
Δ −14.5 pp
———————congress
LIGHTEN (HS-20094-301)15 mgobesity china48604−19.3 % vs −2.7 %
Δ −16.6 pp
−18.7 % vs −2.5 %
Δ −16.2 pp
———————congress

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Notes

Verbatim quotes from the source (6)
  • 5 mg · weight_tp · EQS release
    Under the treatment-regimen estimand, mean body weight reductions were
  • 5 mg · weight_eff · EQS release
    under the efficacy estimand, mean body weight reductions at week 48
  • 10 mg · weight_tp · EQS release
    Under the treatment-regimen estimand, mean body weight reductions were
  • 10 mg · weight_eff · EQS release
    under the efficacy estimand, mean body weight reductions at week 48
  • 15 mg · weight_tp · EQS release
    Under the treatment-regimen estimand, mean body weight reductions were
  • 15 mg · weight_eff · EQS release
    under the efficacy estimand, mean body weight reductions at week 48

Registered trials (4)

From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.

TrialIndicationPhaseStatusStart → primary completionnResultRegistry
RISE-1
Efficacy And Safety of Olatorepatide in Adults With Overweight or Obesity Without Diabetes
ObesityPhase 3not yet recruiting2026-11 → 2028-123000not yet recruitingNCT07896265
NCT07156500
A Phase 3 Study of HS-20094 in Patients With T2DM Inadequately Controlled With Diet and Exercise Alone
T2DPhase 3not yet recruiting2025-09 → 2027-03204not yet recruitingNCT07156500
NCT07156539
A Phase 3 Study of HS-20094 in Patients With T2DM
T2DPhase 3not yet recruiting2025-09 → 2027-03546not yet recruitingNCT07156539
NCT06839664 · China
A Study of HS-20094 in Chinese Adults With Overweight or Obesity
ObesityPhase 3completed2024-11 → 2026-01604Completed; results not in the atlas yetNCT06839664

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: HS-20094. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/hs-20094/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.